Pituitary apoplexy score, toward standardized decision-making: a descriptive study

Pituitary. 2024 Feb;27(1):77-87. doi: 10.1007/s11102-023-01372-x. Epub 2023 Dec 27.

Abstract

Pituitary apoplexy (PA), a rare and life-threatening complication of pituitary adenomas, prompts urgent glucocorticoid administration. The optimal surgical approach is debated, and the Pituitary Apoplexy Score (PAS) aids decision-making. Our retrospective study (2003-2022) assesses variables in PA patient groups (surgical vs. non-surgical), applying PAS to establish a significant threshold for surgical decisions. Additionally, we aim to compare the rates of ophthalmological and endocrine deficit between both groups and identify any associated variables. PAS discrepancies were observed, with averages of 1.7 ± 1.7 (p < 0.0001) for conservative and 3.9 ± 1.7 (p < 0.0001) for surgical groups, confirmed by multivariate analysis (p = 0.009). A PAS threshold of 5, showing over 80% positive predictive value, was established. Patients with low prolactin levels (< 5 ng/ml) had higher corticotropic deficiency prevalence at 3-month and 1-year follow-ups (p = 0.017 and 0.027). Our study supports PAS as a valuable PA management tool, suggesting potential variable adjustments. Multicenter studies are crucial due to PA's low incidence.

Keywords: Pituitary; Pituitary Apoplexy Score (PAS); Pituitary apoplexy.

MeSH terms

  • Adenoma* / surgery
  • Glucocorticoids
  • Humans
  • Pituitary Apoplexy*
  • Pituitary Neoplasms* / surgery
  • Retrospective Studies

Substances

  • Glucocorticoids